Home › Encyclopedia › LL-37 Peptide: Research Status and Clinical Trial Overview
Research / Unapproved

LL-37 Peptide: Research Status and Clinical Trial Overview

Molecular formulaC205H340N60O53
Molecular weight4493 g/mol
Registered trials61
PubChem CID16198951

What LL-37 Is

LL-37 is a peptide compound (molecular formula C205H340N60O53) that has not been approved by any regulatory agency for medical use. It is classified for research purposes only, and no drug label or approved indication exists for this compound. It carries the PubChem identifier CID 16198951.

Clinical Trial Landscape

Public trial registries list 61 registered studies involving LL-37. These studies span a range of research areas rather than a single defined use.

Among the sampled studies, one Phase 2 trial titled "Immune Reconstitution in Tuberculosis Disease" has been completed. Other listed studies, including research on probiotic intervention and intestinal and immune function, and a study examining Antarctic environmental effects on vitamin D and health biomarkers, are either completed or not yet recruiting. These titles reflect the breadth of contexts in which LL-37 has been studied, not a confirmed therapeutic role.

FAQ

Is LL-37 an FDA-approved drug?
No. LL-37 has no approved drug label and is classified as an unapproved research compound. It is not indicated for the treatment, cure, or prevention of any disease.
What is LL-37?
LL-37 is a peptide with the molecular formula C205H340N60O53, identified in chemical databases under PubChem CID 16198951. It has been studied in various research contexts but lacks an approved medical use.
How many clinical trials have studied LL-37?
Public registries list 61 registered trials that reference LL-37. These trials cover a range of research areas and include studies in different phases and statuses, from not yet recruiting to completed.
What kinds of studies have involved LL-37?
Sampled trials include a completed Phase 2 study on immune reconstitution in tuberculosis disease, a study on probiotic effects on intestinal and immune function, and research on health biomarkers in an Antarctic environment. These examples show the variety of research settings rather than a single confirmed application.
Are there known side effects of LL-37?
No adverse event report data is currently available for LL-37 in this monograph. This absence reflects a lack of reported data, not confirmation of safety.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem ClinicalTrials.gov

Updated 2026-09-19